<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Quinolones; Nalidixic acid; Norfloxacin; Ciprofloxacin; Chlamydia: quinolones, in; Ofloxacin; Levofloxacin; Moxifloxacin; Anthrax: antibacterial treatment" /><meta name="IX" content="Quinolones; Nalidixic acid; Norfloxacin; Ciprofloxacin; Chlamydia: quinolones, in; Ofloxacin; Levofloxacin; Moxifloxacin; Anthrax: antibacterial treatment" /><title>5.1.12 Quinolones: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="3944.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="3944.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=3944.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2071.htm">5 Infections</a> &gt; <a href="3705.htm">5.1 Antibacterial drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3942.htm" title="Previous: TINIDAZOLE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="3945.htm" title="Next: CIPROFLOXACIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_3944">5.1.12 Quinolones</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i193.htm" title="Go to appendix 1">Quinolones</a>).</div><div><p><b><span>Nalidixic acid</span></b> and <b><span>norfloxacin</span></b> are effective in
uncomplicated urinary-tract infections.</p><p><b><span>Ciprofloxacin</span></b> is active against both Gram-positive
and Gram-negative bacteria. It is particularly active against Gram-negative
bacteria, including salmonella, shigella, campylobacter, neisseria,
and pseudomonas. <span>Ciprofloxacin</span> has only moderate
activity against Gram-positive bacteria such as <span class="cAC">Streptococcus
pneumoniae</span> and <span class="cAC">Enterococcus faecalis</span>; it should not be used for pneumococcal pneumonia. It is active
against chlamydia and some mycobacteria. Most anaerobic organisms are not susceptible. <span>Ciprofloxacin</span> can be used for respiratory tract infections
(but not for pneumococcal pneumonia), urinary-tract infections, infections
of the gastro-intestinal system (including typhoid fever), bone and
joint infections, gonorrhoea and septicaemia caused by sensitive organisms.</p><p><b><span>Ofloxacin</span></b> is used for urinary-tract infections,
lower respiratory-tract infections, gonorrhoea, and non-gonococcal
urethritis and cervicitis.</p><p><b><span>Levofloxacin</span></b> is active against Gram-positive and
Gram-negative organisms. It has greater activity against pneumococci
than <span>ciprofloxacin</span>. <span>Levofloxacin is licensed
for community-acquired pneumonia but it is considered to be <b>second-line treatment</b> for this indication.</span></p><p>Although <span>ciprofloxacin</span>, <span>levofloxacin</span>, <span>moxifloxacin</span>, and <span>ofloxacin</span> are licensed for skin and soft-tissue infections, many staphylococci
are resistant to the quinolones and their use should be avoided in
MRSA infections.</p><p><b><span>Moxifloxacin</span></b> should be reserved for the treatment
of sinusitis, community-acquired pneumonia, exacerbations of chronic
bronchitis, mild to moderate pelvic inflammatory disease, or complicated
skin and soft-tissue infections which have failed to respond to other
antibacterials or for patients who cannot be treated with other antibacterials.
It has been associated with QT interval prolongation and life-threatening
hepatotoxicity. Moxifloxacin is active against Gram-positive and Gram-negative
organisms. It has greater activity against Gram-positive organisms,
including pneumococci, than ciprofloxacin. Moxifloxacin is not active
against <span class="cAC">Pseudomonas aeruginosa</span> or meticillin-resistant <span class="cAC">Staphylococcus aureus</span> (MRSA).</p><div id="_3944.1"><div class="cAZ"><h2>Anthrax</h2> <p class="cAX"><i>Inhalation</i> or <i>gastro-intestinal
anthrax</i> should be treated initially with either <b><span>ciprofloxacin</span></b> [not licensed for gastro-intestinal
anthrax] or <b><span>doxycycline</span></b> [unlicensed
indication] (<a title="Tetracyclines" href="3804.htm#_3804">section
5.1.3</a>) combined with one or two other antibacterials (such
as <span>amoxicillin</span>, <span>benzylpenicillin</span>, <span>chloramphenicol</span>, <span>clarithromycin</span>, <span>clindamycin</span>, <span>imipenem with cilastatin</span>, <span>rifampicin</span> [unlicensed indication], and <span>vancomycin</span>). When the condition improves and the sensitivity
of the <span class="cAC">Bacillus anthracis</span> strain is known, treatment
may be switched to a single antibacterial. Treatment should continue
for 60 days because germination may be delayed.</p><p><i>Cutaneous anthrax</i> should be treated with either <span>ciprofloxacin</span> [unlicensed indication] or <span>doxycycline</span> [unlicensed indication] (<a title="Tetracyclines" href="3804.htm#_3804">section
5.1.3</a>) for 7 days. Treatment may be switched to amoxicillin
(<a title="monograph: AMOXICILLIN" href="3724.htm#_3724">section 5.1.1.3</a>) if the infecting strain is susceptible. Treatment
may need to be extended to 60 days if exposure is due to aerosol.
A combination of antibacterials for 14 days is recommended for cutaneous
anthrax with systemic features, extensive oedema, or lesions of the
head or neck.</p><p><span>Ciprofloxacin</span> or <span>doxycycline</span> may be given for <i>post-exposure prophylaxis</i>. If
exposure is confirmed, antibacterial prophylaxis should continue for
60 days. Antibacterial prophylaxis may be switched to amoxicillin
after 10–14 days if the strain of <span class="cAC">B. anthracis</span> is susceptible. Vaccination against anthrax (<a title="Anthrax vaccine" href="6455.htm#_6455">section
14.4</a>) may allow the duration of antibacterial prophylaxis to
be shortened.</p></div></div><div id="_3944.2"><div class="cAZ"><h2>Cautions</h2> <p class="cAX">Quinolones should be used with caution
in patients with a history of epilepsy or conditions that predispose to seizures, in G6PD deficiency (<a title=" G6PD deficiency" href="4925.htm#_4925">section 9.1.5</a>), myasthenia gravis (risk of exacerbation), and in children or adolescents (arthropathy
has developed in weight-bearing joints in young <i>animals</i>—see below). Exposure to excessive sunlight should be
avoided (discontinue if photosensitivity
occurs). Quinolones can prolong the QT interval. Moxifloxacin
is contra-indicated in patients with risk factors for QT interval
prolongation (e.g. electrolyte disturbances, acute myocardial infarction,
heart failure with reduced left ventricular ejection fraction, bradycardia,
congenital long QT syndrome, concomitant use with other drugs known
to prolong the QT interval, history of symptomatic arrhythmias) and
the other quinolones should be used with caution in these patients. The CSM has warned that quinolones may induce <b>convulsions</b> in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce
them. Other <b>interactions:</b> Appendix 1 (quinolones).</p><div class="cAR"><h3>Use in children</h3> <p class="cAX">Quinolones cause arthropathy in
the weight-bearing joints of immature <i>animals</i> and
are therefore generally not recommended in children and growing adolescents.
However, the significance of this effect in humans is uncertain and
in some specific circumstances short-term use of either ciprofloxacin
or nalidixic acid may be justified in children. For further details
see <a href="http://www.medicinescomplete.com/mc/bnfc/current/3944.htm" title="BNFC:sub-section: Quinolones"><i>BNF for Children</i></a>.</p></div></div><div class="cN"><h3 class="cBP">Tendon damage</h3><p>Tendon damage (including rupture) has been reported rarely in
patients receiving quinolones. Tendon rupture may occur within 48
hours of starting treatment; cases have also been reported several
months after stopping a quinolone. Healthcare professionals are reminded
that:</p><ul class="cBF"><li><p class="cQ">quinolones are contra-indicated in patients with a history of tendon disorders related to quinolone use;</p></li><li><p class="cQ">patients over 60 years of age are more prone
to tendon damage;</p></li><li><p class="cQ">the risk of tendon damage is increased by
the concomitant use of corticosteroids;</p></li><li><p class="cQ">if tendinitis is suspected, the quinolone
should be discontinued immediately.</p></li></ul></div><div class="cAZ"><h2>Contra-indications</h2> <p class="cAX">quinolone hypersensitivity. See also <a title="BNF:target-block: Quinolone cautions" href="3944.htm#_3944.2">Cautions above</a>.</p></div></div><div id="_217709"></div><div id="_217710"></div><div id="_204191"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Quinolones should be avoided in pregnancy
because they have been shown to cause arthropathy in <i>animal</i> studies; safer alternatives are available; however, a single dose
of ciprofloxacin may be used for the prevention of a secondary case
of meningococcal meningitis</p></div></div><div id="_218829"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX">Side-effects of the quinolones include
nausea, vomiting, dyspepsia, abdominal pain, diarrhoea (rarely antibiotic-associated
colitis), headache, dizziness, rash (very rarely Stevens-Johnson syndrome
and toxic epidermal necrolysis). Less frequent side-effects include
anorexia, sleep disturbances, asthenia, confusion, anxiety, depression,
hallucinations, tremor, blood disorders (including eosinophilia, leucopenia,
thrombocytopenia), arthralgia, myalgia, disturbances in vision and
taste. Other side-effects reported rarely or very rarely include hepatic
dysfunction (including jaundice and hepatitis), hypotension, vasculitis,
dyspnoea (more frequent with moxifloxacin), convulsions, psychoses,
paraesthesia, renal failure, interstitial nephritis, tendon inflammation
and damage (see also Tendon Damage above), photosensitivity, disturbances
in hearing and smell. The drug should be <b>discontinued</b> if psychiatric, neurological or hypersensitivity reactions (including
severe rash) occur.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_3945"><a href="3945.htm" title="CIPROFLOXACIN">CIPROFLOXACIN</a></li><li id="_69969"><a href="69969.htm" title="LEVOFLOXACIN">LEVOFLOXACIN</a></li><li id="_127959"><a href="127959.htm" title="MOXIFLOXACIN">MOXIFLOXACIN</a></li><li id="_3951"><a href="3951.htm" title="NALIDIXIC ACID">NALIDIXIC ACID</a></li><li id="_3956"><a href="3956.htm" title="NORFLOXACIN">NORFLOXACIN</a></li><li id="_3958"><a href="3958.htm" title="OFLOXACIN">OFLOXACIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3942.htm">Previous: TINIDAZOLE</a> | <a class="top" href="3944.htm#">Top</a> | <a accesskey="]" href="3945.htm">Next: CIPROFLOXACIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>